At the closing bell on the stock market today, Alder popped 6.7%, to 17.65. Shares of Teva dipped a fraction, to 23.76. Rival Eli Lilly (LLY) rose a fraction and Amgen (AMGN), which was the first to get a migraine prevention drug to market, dipped 0.4%.
Teva studied fremanezumab in chronic and episodic cluster headaches, as well as a long-term safety study. Researchers found fremanezumab is unlikely to work in chronic cluster headaches during the 12-week treatment period, and ended that study.
Fremanezumab belongs to a class called anti-CGRP drugs, which aim to block a specific peptide associated with migraines. It’s possible anti-CGRP drugs could have other uses, Teva spokesperson Tushar Shah said in a statement.
«While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine, where calcitonin gene-related peptide plays a contributory role in their pathophysiology,» he said.
Other Anti-CGRP Drugs
Amgen and partner Novartis (NVS) grabbed approval in May for anti-CGRP drug Aimovig in migraine prevention. For the week ended June 8, Aimovig prescriptions grew 102% week over week to 2,129, RBC analyst Kennan MacKay said in a note.
Alder is testing its drug, eptinezumab, as a preventive treatment for episodic and chronic migraines. It also has a migraine prevention drug in preclinical studies. Lilly’s galcanezumab is under review in migraine prevention and is also being studied in cluster headaches.
Meanwhile, Biohaven Pharmaceutical (BHVN) has an anti-CGRP drug in development as an acute treatment for migraines. It’s also testing another anti-CGRP drug to treat and prevent migraines. Allergan (AGN), too, has an anti-CGRP in development as an acute treatment for migraines.
A Product Manager with expertise in pharma marketing and sales operations